Apotex has invested over $2 billion to research and development over the past 10 years — more than any other pharmaceutical company in Canada, brand or generic.

In fact, Apotex will continue to lead in these expenditures and has committed over $2.1 billion to research and development over the next 10 years. We do this to ensure that patient needs will continue to be met in the future according to the high standards of quality and overall coverage that we have established.

Sustained Research and
Development Expenditures

2005 – 2014

$2,045,537,000

  • $183,141,000
  • $178,757,000
  • $181,818,000
  • $218,944,000
  • $188,733,000
  • $178,852,000
  • $174,003,000
  • $207,745,000
  • $222,439,000
  • $311,105,000

And while we’re a global company, we remain committed to the Canadian marketplace like no other generic manufacturer. We employ over 6,000 people in Canada alone, who all share our vision of providing high-quality medication at an affordable price.

Because of our significant presence and investment in Canada, you can be assured that our domestic needs are always a priority.

Additionally, we’ve spent over $2 billion on land and facilities in Canada, which has helped stimulate the economy directly. This demonstrates just how seriously we take our commitment to the fiscal future of Canada.

Our Etobicoke facility alone is over 600,000 square feet. In 2005, it underwent a $250 million expansion, increasing capacity from 2 billion to 8 billion doses per year.

Canada
Tap to view information about our Etobicoke facility
Tap to view information about our Etobicoke facility